A syndrome of microangiopathic hemolytic anemia, renal dysfunction and neurological abnormalities was first noted in bone marrow transplant recipients 22 years ago. Now known as transplantation-associated thrombotic microangiopathy (TA-TMA) to distinguish it from other thrombotic microangiopathies, this disorder responds poorly to conventional treatments for thrombotic thrombocytopenic purpura. In this review, we discuss the incidence and risk factors for TA-TMA and describe a pathophysiologic model of the disorder based on results obtained from laboratory models of the thrombotic microangiopathies. We conclude by suggesting possible approaches to the early diagnosis and treatment of TA-TMA based on this model that may warrant testing in future clinical trials.
Transplantation-associated thrombotic microangiopathy (TA-TMA) continues to frustrate clinicians involved in the care of transplant recipients 22 years after it was first described. 1 Recent work has led to an improvement in our understanding of the pathophysiology of this disorder, while new experimental models of thrombotic microangiopathies give reason to hope that effective treatment may one day become available.
Clinical features
The thrombotic microangiopathies are a group of disorders characterized by the intravascular activation of platelets, resulting in the formation of platelet-fibrin thrombi within the microcirculation. The clinical manifestations of these disorders result from the obstruction of the microcircuCorrespondence: Dr A Daly, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada lation, and ultimately depend on the distribution of involved vascular beds. In this regard, epidemic hemolytic-uremic syndrome (HUS) and sporadic thrombotic thrombocytopenic purpura (TTP) lie at opposite ends of a clinical spectrum, with predominant involvement of the renal microcirculation in the former disorder and more widespread involvement, including the central nervous system, in the latter. The hallmark feature of this obstructed microcirculation is microangiopathic hemolytic anemia, which is characterized by fragmentation of erythrocytes and the characteristic presence of schistocytes seen on examination of the peripheral blood film. Consumption of platelets and erythrocytes in this process leads to thrombocytopenia and anemia. Biochemical evidence of hemolysis, including increased lactate dehydrogenase (LD) and serum bilirubin and decreased serum haptoglobin, accompanies red blood cell fragmentation, when severe, frank hemoglobinuria may be observed. In addition to microangiopathic hemolytic anemia and thrombocytopenia, the classical diagnostic pentad of TTP also includes renal failure, fever and neurological abnormalities.
It can often be difficult to establish a diagnosis of TA-TMA in bone marrow transplant recipients. These patients frequently have multiple potential etiologies for renal dysfunction and fever and may display only subtle neurological abnormalities. Persistent anemia or thrombocytopenia may be mistakenly ascribed to delayed engraftment of red blood cells or platelets, to the effects of myelosuppressive medications, infection or GVHD rather than to consumption. In addition, the presentation of TA-TMA is highly heterogeneous, ranging from asymptomatic, low-level red blood cell fragmentation to fulminant disease. 2 The diagnosis of TA-TMA is made most reliably by examination of the peripheral blood film for red blood cell fragments. We have observed that an increase in the number of red blood cell fragments and the biochemical evidence of hemolysis over several observations can make the diagnosis more convincingly than finding features compatible with the diagnosis of TA-TMA on a single occasion. For this reason it is essential that blood films be reviewed and reported by experienced staff and that reliable quantitative evaluations of red blood cell fragmentation be available.
The clinical heterogeneity of TA-TMA was addressed by Pettitt and Clarke, 2 who proposed a classification system consisting of four overlapping subtypes of TMA that occur (Table 2) . 3 Low level schistocytosis without features of thrombotic microangiopathy can also be observed in severe liver and kidney disease, and in the postsplenectomy state, further complicating the diagnosis in this group of patients.
Incidence and risk factors for TA-TMA
The exact incidence rate of TA-TMA is difficult to determine from the published literature due to differences in case definition, reporting bias and missed diagnoses. As a result, reported incidence rates have varied widely, ranging from 0% to 74%. 4 In a retrospective survey of Italian bone marrow transplant centers, Iacopino and coworkers 5 identified 12 patients who received treatment for TA-TMA among 4334 patients treated in 25 transplant centers over a 10-year period. The overall incidence reported in their experience is 0.28% based upon detecting microangiopathic hemolytic anemia and at least two other features of TTP/HUS. Rabinowe and colleagues 6 diagnosed TA-TMA in patients having a sudden and persistent decrease in hemoglobin and platelets in conjunction with persistent elevations in creatinine and LD. Other causes, such as autoimmune hemolytic anemia and thrombocytopenia, and disseminated intravascular coagulation, were ruled out. Sixteen of 168 autologous and allogeneic bone marrow transplant recipients (9.5%) met this case definition in this study. 6 Pettitt and Clarke 2 report an incidence rate of 6.4% overall, noting that rates are higher in certain subgroups, such as recipients of allogeneic bone marrow transplants. Twenty-two patients (4.8%) were diagnosed with TA-TMA among 456 recipients of allogeneic bone marrow transplants treated by the Bristol Bone Marrow Transplant Unit. 7 A prospective analysis using standardized diagnostic criteria will be necessary to determine the exact incidence of this disorder.
The earliest reports of TA-TMA in bone marrow transplant recipients identified the use of cyclosporin A for the prevention and treatment of acute graft-versus-host disease (GVHD) prophylaxis as a possible risk factor. 1, 8 While cyclosporin is most often implicated as the cause of this syndrome in bone marrow and in solid organ transplant recipients, 4,9 a number of other risk factors have also been described. The observation that TA-TMA may occur in autologous blood stem cell transplant recipients suggests that high-dose chemotherapy alone may be responsible for some cases of this disorder. 6 Others have associated total body irradiation, 10 GVHD 11 and intensive immunosuppression 12 with the development of this syndrome. Infections such as CMV and HHV-6 have been associated in case reports with TA-TMA. 13, 14 Recent reports have also documented the occurrence of TA-TMA in solid organ and bone marrow transplant recipients receiving immunosuppression with tacrolimus. 15 Two recent case-control studies have examined risk factors for TA-TMA in allogeneic bone marrow transplant recipients in more detail. Fuge et al 7 examined 22 cases of TA-TMA occurring over a 6-year period among patients admitted to a combined pediatric and adult bone marrow transplant unit. Patients with TA-TMA were more likely to be female and were significantly older than patients who did not develop TA-TMA. When the analysis was restricted to recipients of bone marrow transplants from unrelated donors, grade II-IV acute GVHD also emerged as a risk factor. In our experience hepatic veno-occlusive disease (P = 0.034) and grade II-IV acute GVHD (P = 0.042) were associated with an increased risk of TA-TMA. In a separate analysis we found that transplantation from an unrelated donor was associated with a 3.4-fold increase in the relative risk of developing TA-TMA, compared to recipients of bone marrow from related donors (P = 0.002). In our patient population, which excluded pediatric patients, age was not a risk factor.
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Pathophysiology of TA-TMA
Unlike the situation in most cases of classical TTP, in which a deficiency of metalloprotease activity leads to the accumulation of unusually large prothrombotic von Willebrand factor (vWF) multimers and to thrombosis, the situation in other thrombotic microangiopathies is less clear. [17] [18] [19] Recent studies have demonstrated that vWF cleaving metalloprotease activity is generally preserved in the transplantation-associated form of this disease. [20] [21] [22] However, as with classical TTP, abnormalities of the vascular endothelium have been described on ultrastructural examination which are felt to be central to the pathogenesis of this disorder. 23 Recent work in classical TTP has shown that other mechanisms, in addition to metalloprotease deficiency, may contribute to vascular endothelial damage, and these mechanisms may have relevance to TA-TMA. It has been demonstrated by Laurence et al 24 that plasma from approximately 75% of patients with classical TTP or HUS can induce apoptosis in cultured microvascular endothelial cells. 24 In this model, apoptosis is restricted to primary microvascular endothelial cells of renal, cerebral and dermal origin, but is not observed in large vessel or pulmonary endothelial cell cultures. This pattern of selective endothelial cell apoptosis reflects the organ distribution of platelet-rich thrombi observed clinically in these disorders. 25, 26 This form of injury has been shown to correlate with the generation of platelet microparticles in vitro and in patients with classical TTP. 27 The mechanism of apoptosis appears to be linked to the rapid induction of Fas (CD95) on cultured microvascular endothelium and can be blocked in vitro by anti-Fas antibodies, normal cryo-poor plasma and low concentrations of the nonspecific protease and endonuclease inhibitor aurintricarboxylic acid. Inhibitors of caspases-1 and 3 and overexpression of Bcl-X L in cultured microvascular endothelial cells suppress the induction of apoptosis in these cells by TTP plasma. 28 Apoptosis of microvascular endothelial cells may represent a final common pathway of injury leading to the clinical expression of microangiopathic hemolytic anemia.
In bone marrow transplantation, multiple insults may lead to the initiation of endothelial cell injury or dysfunction (Figure 1 high-dose chemotherapy and radiotherapy may injure endothelial cells, either by direct mechanisms or through the induction of cytokines. Levels of the cytokines interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-␣) and interferon gamma (IFN-␥) are increased following conditioning and increased levels are also associated with the development of acute GVHD and hepatic veno-occlusive disease. TNF-␣ can induce apoptosis of cultured endothelial cells and together with IL-1 increases expression of tissue factor and plasminogen activator inhibitor-1 and -2 (PAI-1 and 2). The endothelial cell surface is also altered by TNF-␣ to promote leukocyte adhesion through the up-regulation of E-selectin, ICAM-1 and PECAM-1. 29 IFN-␥, produced by alloreactive T-lymphocytes, may act directly to prime monocytes and macrophages. Activation of these cells by a variety of stimuli, including the translocation of endotoxin facilitated by conditioning or GVHD-related mucosal damage, leads to further cytokine production and tissue injury. 30 Cyclosporin may promote procoagulant changes in the endothelium by increasing the synthesis of thromboxane A 2 and decreasing the production of prostacycline (PGI 2 ).
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Animal models of thrombotic microangiopathies
Research into the pathogenesis and treatment of the thrombotic microangiopathies has been hampered by the lack of suitable animal models. Attempts to mimic Shiga-toxininduced HUS in rodents failed because these animals do not express the Shiga-toxin globoside receptor Gb3. One recent approach to induce HUS in laboratory animals has been to infuse antibodies reactive against endothelial cell or platelet surface components. Antibodies raised against cultured rat glomerular endothelial cells induce microangiopathic hemolytic anemia and renal dysfunction when selectively infused into the renal artery of rats. Histologically, swelling and focal denudation of endothelium is observed with varying degrees of tubular necrosis. Marked intravascular platelet aggregation is observed within 10 min of the infusion and fibrin deposition is also observed in this model. 33 More recently it has been observed that vascular endothelial growth factor (VEGF) accelerates renal recovery and protects rats from renal infarction in this model. 34, 35 The mechanism of this protection may be through maintenance of normal endothelial nitric oxide production and through the prevention of apoptosis.
Thrombotic microangiopathies have been observed in primate models of non-myeloablative transplantation of xenogeneic blood stem cells and following high-dose chemotherapy. Baboons transplanted with growth factor mobilized porcine blood stem cells following non-myeloablative conditioning developed changes of microangiopathic hemolytic anemia 1-2 days following transplantation. 36 The rapid induction of these changes in this model is likely related to the infusion of large numbers of xenogeneic cells where the contribution of naturally occurring antibodies to non-primate-specific carbohydrate moieties cannot be excluded. Microangiopathic hemolytic anemia has also been observed in rhesus monkeys following highdose chemotherapy consisting of either cyclophosphamide 180 mg/kg or lower doses of cyclophosphamide in combination with carboplatin. In this model the vWF multimer size distribution was not altered. Renal dysfunction was an important component of this process, which was fatal in the four cases studied.
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Treatment of transplantation-associated thrombotic microangiopathy
At the present time there is no consensus on what constitutes appropriate therapy for patients with TA-TMA. By analogy with the treatment of classical TTP, many centers employ plasma exchange in the therapy of TA-TMA, 38 although there are no large-scale clinical trials to support its use in this disorder. Initial treatment usually consists of withdrawal of cyclosporin or tacrolimus and replacement of these agents with alternative immunosuppressive medications. Mycophenolate mofetil, azathioprine and anti-T cell antibody therapies have been reported as appropriate alternatives, although the use of these agents may be associated with dose limiting myelosuppression in bone marrow transplant recipients. 15, 39 In addition, mycophenolate mofetil and azathioprine may be associated with a delayed onset of action, necessitating the addition of increased doses of corticosteroids in cases in which TA-TMA occurs on a background of GVHD.
The role of plasma exchange in the management of this disorder is controversial. 40 While response rates as high as 75% have been reported in classical TTP, 41 response rates in TA-TMA have been considerably lower and long-term survival rates have been disappointing (see Table 3 ). Overall, just under half of patients in nine reported case series have achieved a complete or partial response to plasma exchange according to a variety of response criteria. What seems clear from these reports, however, is that fewer than half of patients who respond to plasma exchange therapy experience prolonged survival. Many of the patients in these reports died of causes other than TA-TMA, most commonly infection, GVHD, and multisystem organ failure syndrome. In all cases cyclosporin was discontinued at the time of diagnosis of TA-TMA, and the effect of this intervention in isolation cannot be determined as patients then went on to have therapeutic plasma exchange. In addition, patients within case series were often treated with different modalities, such as protein A immunoadsorption and administration of chemotherapeutic or immunosuppressive agents such as vincristine or steroids, or splenectomy.
Future directions in diagnosis and management of TA-TMA
Early detection of TA-TMA may allow for the early evaluation of the patient for potentially reversible contributing risk factors at a point at which the course of the disease may be modified. It is expected that once extensive endothelial dysfunction occurs it would be more difficult to obtain benefit from risk factor modification and supportive care. It is possible that the demonstration of TA-TMA-associated coagulation abnormalities, such as increased levels of vWF, PAI-1 or of TM, 48, 49 or indicators of endothelial dysfunction, such as the generation of endothelial microparticles, 27 may predict the subsequent development of this disorder. Conditioning regimens have been shown to alter levels of vWF, PAI-1 and TM and baseline values for these factors in this context remain to be determined. It also remains to be shown whether platelet microparticles are generated in the transplantation-associated form of thrombotic microangiopathy.
The early detection of this disorder will also allow for potential intervention with biologically directed therapies. Such therapies have been shown to be highly effective in the management of disorders, such as acute promyelocytic leukemia and chronic myeloid leukemia and rationally designed therapies may be of benefit in TA-TMA as well. Interventions directed at improving endothelial cell function, accelerating endothelial cell recovery from injury and preventing apoptosis of these cells are potential goals for future developmental therapies. Agents that might be expected to influence the disease course in bone marrow transplant patients are listed in Table 4 . VEGF has been shown to promote recovery of endothelial cell function and to prevent apoptosis in response to inflammatory cytokines such as TNF␣. 34, 35, 50 VEGF stimulation of endothelial cells in culture has also been shown to promote platelet adhesion and activation, which may limit its clinical application in this setting. 51 Erythropoietin has been shown to inhibit apoptosis in cultured bovine aortic endothelial cells in response to endotoxin. 52 Initial experience with aurintricarboxylic acid, a potent inhibitor of apoptosis, indicates that it inhibits TTP-plasma induced endothelial apoptosis in vitro, but its toxicity appears to preclude its clinical use. 53 TNF␣ appears to be an important cytokine mediator of GVHD and may also be important in the initiation of TA-TMA. Agents that block the action of TNF␣ such as etanercept (Enbrel) and infliximab (Remicade), may have benefit in the treatment of GVHD and we speculate that they may also be beneficial in TA-TMA. Defibrotide, which has been 713 Table 3 Treatment of transplantation-associated thrombotic microangiopathy by plasma exchange therapy shown to improve outcome in patients with severe hepatic veno-occlusive disease, 54 also prevents TNF␣-induced endothelial cell apoptosis in vitro. 55 In a recently reported case series nine responses were seen in a group of 12 patients with moderate to severe TA-TMA after prolonged treatment, suggesting the need for randomized trials of defibrotide in this disorder. 56 Agents that maintain the normal anticoagulant endothelial surface, such as nitric oxide donors and defibrotide, which inhibit platelet aggregation and promote vasodilation, may also alter the course of this disease in bone marrow transplant recipients. 57, 58 
